Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
Source: MDLinx, September 2020
Researchers reviewed the prescribing of first?line checkpoint inhibitors (CPIs) for the treatment of patients with metastatic melanoma in England since their introduction in 2014 to better understand the clinical practice and used national databases to link outcomes such as survival and treatment toxicity of treated patients.
Five thousand four hundred sixty-five melanoma patients were diagnosed and treated with systemic anticancer therapy between April 2014 and March 2018, of which 2,322 received first?line CPIs.
